SecBot SecBot
8-K ·Filed Mar 5, 2026

KURA

Kura Oncology, Inc.
MIXED
Impact 6/10
Horizonweeks Processed8mo ago SEC0001193125-26-092465
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

Monitor upcoming clinical data milestones in 2026 and track sequential revenue growth of KOMZIFTI as indicators of commercial success, while watching cash burn rate given the significant increase in operating expenses.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$8.51
T+0 close · Mar 5, 2026 · via day close
Latest settled
+6.17%
T+60 · $9.04
Vs SPY
−5.13%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 5 $8.51entry
  2. T+1 · 9mo ago +5.29%α +6.60% · $8.96
  3. T+5 · 8mo ago +3.88%α +6.12% · $8.84
  4. T+20 · 8mo ago +1.18%α +4.96% · $8.61
  5. T+60 · 6mo ago +6.17%α −5.13% · $9.04
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Kura Oncology reported its first commercial revenue of $2.1 million from KOMZIFTI, its newly approved AML drug, in Q4 2025. Despite this milestone, the company reported a significant net loss increase to $81 million due to higher R&D and commercialization expenses. The company maintains a strong cash position of $667.2 million and anticipates $180 million in collaboration payments.

Key Financial Metrics

Revenue
$17.3M
-67.8% YoY
EPS
$-1.84

Key Facts

  • Generated $2.1 million in net product revenue from KOMZIFTI in Q4 2025 (first five weeks of sales)
  • Net loss increased to $81 million in Q4 2025 from $19.2 million in Q4 2024
  • Cash position of $667.2 million as of December 31, 2025
  • Anticipates $180 million in collaboration payments from Kyowa Kirin
  • R&D expenses increased to $64.4 million from $52.3 million year-over-year

Financial Impact

Q4 2025 net loss of $81 million on $17.3 million in total revenue

revenuenet lossR&D expensesSG&A expensescash position

Segment Breakdown

SegmentRevenueGrowth
Product revenue, net$2.1MNot reported
Collaboration revenue$15.2M-71.8%

Risk Factors

  • High cash burn rate with increasing R&D and commercialization expenses
  • Limited commercial track record with KOMZIFTI revenue based on only five weeks of sales
  • Dependence on anticipated $180 million in future collaboration payments

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-092465
Document: kura-20260305.htm0001193125-26-092465
Document: 0001193125-26-092465-index-headers.html0001193125-26-092465
Document: 0001193125-26-092465-index.html0001193125-26-092465
Document: 0001193125-26-092465.txt0001193125-26-092465

Track record

29 reports on KURA

Performance horizon

6 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +52.28% at T+60 after the Jun 3, 2026 report. 10 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today Insider Buy Bullish 5/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
  2. Nov 16, 2026today 144 Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
  4. Nov 10, 20266d ago S-3ASR Neutral 4/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
  5. Nov 10, 20266d ago Press Release Neutral 5/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
  6. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $7.61 Now $7.09 −6.83% settles Feb 2
  7. Sep 29, 20266w ago Insider Cluster Bearish 5/10 Entry $10.71 Now $7.09 +33.80% settles Dec 24
  8. Sep 29, 20266w ago Press Release Bullish 6/10 Entry $10.81 Now $7.09 −34.38% settles Dec 23
  9. Sep 9, 20269w ago 8-K Bullish 6/10 Entry $12.09 Now $7.09 −41.36% settles Dec 3
  10. Sep 8, 20269w ago 8-K Neutral 2/10 Entry $12.52 Now $7.09 −43.37% settles Dec 2
Showing 10 of 29

US Market Status

Market Closed · Opens in 7h 5m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 5, 2026